Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Precision medicines exert selective pressure on tumour cells that leads to the preferential
growth of resistant subpopulations, necessitating the development of next-generation
therapies to treat the evolving cancer. The PIK3CA–AKT–mTOR pathway is one of the most
commonly activated pathways in human cancers, which has led to the development of small-
molecule inhibitors that target various nodes in the pathway. Among these agents, first-
generation mTOR inhibitors (rapalogs) have caused responses in 'N-of-1'cases, and second …
growth of resistant subpopulations, necessitating the development of next-generation
therapies to treat the evolving cancer. The PIK3CA–AKT–mTOR pathway is one of the most
commonly activated pathways in human cancers, which has led to the development of small-
molecule inhibitors that target various nodes in the pathway. Among these agents, first-
generation mTOR inhibitors (rapalogs) have caused responses in 'N-of-1'cases, and second …
[引用][C] Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
K Shokat, VS Rodrik-Outmezguine, M Okaniwa, Z Yao… - 2016 - escholarship.org
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor …
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor …
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. …
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor …
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. …
以上显示的是最相近的搜索结果。 查看全部搜索结果